home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9407f.zip
/
M9471065.TXT
< prev
next >
Wrap
Text File
|
1994-08-09
|
2KB
|
29 lines
Document 1065
DOCN M9471065
TI The retroviral life cycle and safety considerations for retroviral
mediated gene therapy (Meeting abstract).
DT 9409
AU Boris-Lawrie K; Temin HM; McArdle Lab. for Cancer Res., Univ. of
Wisconsin, Madison, WI
SO Gene Therapy for Neoplastic Diseases. June 26-29, 1993, Washington, DC,
A7, 1993.. Unique Identifier : AIDSLINE ICDB/94698154
AB The life cycle of retroviruses makes them uniquely suited as vectors for
gene therapy. Safety is the primary consideration when designing
retroviral vectors and helper cells. Retroviral vectors used for gene
therapy are based on simpler retroviruses (SRV), which do not cause
disease in humans and ungulates. Retroviral disease in these species is
caused by more complex retroviruses (MCRVs). We have converted the
genome structure of an MCRV, bovine leukemia virus (BLV), to resemble
that of a SRV. These simpler BLV vectors can replicate, and animal
studies are underway to determine if the simple BLV is an effective
vaccine against wild-type BLV infection. Preliminary experiments
indicate that a simpler HIV-1 vector can also replicate. SRV versions of
MCRVs may be useful as preventive vaccines against disease caused by
MCRVs.
DE *Gene Therapy Genetic Vectors HIV-1/GENETICS Human
Retroviridae/*GENETICS/PHYSIOLOGY MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).